Invitae issued approximately $21.2 million in shares of its own common stock to former CombiMatrix shareholders.
The company said the planned commercial launch of its noninvasive lung cancer diagnostic has been delayed due to technical issues during the test's validation process.
The companies will use Ymir's urine extracellular vesicle technology and OHSU's Proteomics Shared Resource to develop biomarkers for hepatocellular carcinoma.
The company will use the funds to expand its US-based business and to commercialize its data visualization platform.
Harvard Bioscience will offer Fluxion's BioFlux and IonFlux cellular analysis platforms to its North American customers.
The partners plan to validate blood-based microRNAs as biomarkers for the early detection of pulmonary and neurodegenerative diseases.
Syapse has raised new venture capital to support expansion into community hospitals that want to start precision oncology programs.
Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.
The alliance follows a marketing deal signed with Sysmex Europe that covers Europe, the Middle East, and Africa.
The grant was awarded under a program designed to help small businesses transition NIH-funded projects into the commercialization stage.
The offering was a follow-on to a capital raise during the summer that brought in $6 million. The company's CEO said the additional financing was needed to execute on its business plan.
The company's ThyGenX and ThyraMir tests are designed for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.
The IP is based on the research of Emmanuelle Charpentier from the Hannover Medical School in Germany and Umea University in Sweden.
The company discussed expectations for how its products will fare against rivals into next year based on recent data and coverage decisions, and on expected reimbursement changes.
The company fell short of the consensus Wall Street revenue estimate, while its net loss for the quarter also widened.
The company had $1.1 million in revenue during the quarter, a 10 percent increase year over year despite what the firm said was a 15 to 20 percent sales reduction due to recent hurricanes.
Though revenues from its non-invasive heart transplant rejection test AlloMap fell about 5 percent, CareDx is already being reimbursed by Medicare for its new AlloSure test.
Natera said its liquid biopsy assay Signatera is well suited for the immuno-oncology field, particularly pharmaceutical companies developing personalized vaccines.
The robotic microbial DNA isolation and direct PCR test is designed for routine bacterial and fungal pathogen diagnosis.
The next-generation sequencing-based multiplex assay screens 120 hotspots and 17 exons in 33 known cancer genes.
The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.
Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.
In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.
The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.